


4P Medicine Transforming Clinical Development

Exploring Prevention, Prediction, Precision, and Participation

This infographic outlines how these four pillars have revolutionized personalized healthcare. Discover the impact of integrating Prevention, Prediction, Precision, and Participation in enhancing treatment efficacy and optimizing patient engagement.






Beyond Genetics

Systems Medicine

Systems medicine extends traditional genetic analyses to include data from various biological layers and environmental interactions. It also utilizes comprehensive models to better understand disease mechanisms and individual health dynamics.



Customized Treatments Harness Predictive Data

Through leveraging vast data sets



Genetic factors



Lifestyle factors

Each of these factors can be used to identify individuals at risk before disease onset, enhancing preventive strategies and treatment precision.

Environmental factors

Customized Treatments

for Individual Needs



Evolving Trial Designs

The shift towards personalized medicine requires novel clinical trial designs focusing on individual patient responses rather than average outcomes, leading to more effective and safer treatment options.

Aspect	Traditional Trial Methodologies	Innovative Trial Methodologies
- Patient Focus	Average patient within a homogeneous group	Individual patient with unique genetic, demographic, and environmental factors
Objective	Detect an average treatment effect	Characterize individual differences in molecular processes
Data Integration	Limited, covariate-adjusted designs	High-throughput genomic technologies, proteomics, and metabolomics
Data Complexity	Simple focus on average effects and homogenous groups	Multidimensional patient-level data analysis
Precision	Reduced precision due to challenges in incorporating necessary covariate information	Enhanced precision through personalized data
Design Challenges	Difficulty in recruiting sufficient subjects for subgroup analysis	Establishing a robust statistical framework for personalized data analysis
Regulatory Challenges	Significant challenges, especially for personalized therapies	FDA frameworks and guidance specifically for personalized medicine
Trial Design Examples	Stratified medicine, covariate-adjusted designs	Master protocols, platform trials, and basket trials
Therapeutic Development	Group-based treatment approaches	Individualized treatments, such as antisense oligonucleotides (ASOs)
FDA and EMA Involvement	General regulatory oversight	Specific frameworks by FDA's Division of Translational and Precision Medicine
Technological Integration	Minimal, traditional methodologies	Advanced technologies, including family genome sequencing and single-cell analysis
Example Applications	General therapeutic interventions	Individualized ASOs targeting specific patients

Empowering Patients

Empowering patient participation in clinical trials and healthcare decision-making can improve health outcomes. Engaged patients can also help tailor research and treatment approaches to reflect their needs and preferences.

A "Before" scenario showing patient involvement	Aspect	An "After" scenario showing patient involvement
Limited scale and detail	Database Acquisition and Access	Robust databases enabling patient segmentation and predictive modeling
Passive or minimal	ක්රීම බබ්බ Patient Participation	Active, robust involvement in research activities
Reactive, less structured	Clinical Development Process	Enabling, prospectively planned observational and interventional research
Infrequent or ad-hoc	Evaluation of Factors	Frequent evaluation of facilitatory and inhibitory factors
Less emphasis on physician-patient relationship	Physician's Role	High emphasis on physician-patient relationship and reputation




The shift towards personalized medicine requires novel clinical trial designs focusing on individual patient responses rather than average outcomes, leading to more effective and safer treatment options.

More Information and Resources

worldwide.com

0

info@worldwide.com



SOURCES:

- Alemayehu D, Cappelleri JC. Conceptual and analytical considerations toward the use of patient-reported outcomes in personalized medicine. American health & drug benefits. 2012 Jul;5(5):310.
- Blue Cross of California. Medicare part D coverage criteria. AMPYRA (dalfampridine). January 2012. www.blueshieldca.com/sites/medicare/documents/PA_-CY2012_AMPYRA_dalfampridine_MCweb.pdf. Accessed August 13, 2012.
- Bouchard C: The genetics of obesity: from genetic epidemiology to molecular markers. Mol Med Today 1995, 1:45-50.
- Cella D, Chen CI, Quek RGW, Uribarren A, Reaney M, Mastey V, Collyar D, Chassany O. Patient-reported outcomes labeling for oncology drugs: Multidisciplinary
 perspectives on current status and future directions. Front Pharmacol. 2022 Oct 17;13:1031992. doi: 10.3389/fphar.2022.1031992. PMID: 36339622; PMCID:
 PMC9634749.
- Collins F. Integrating the 4P's into Patient Care. November 2019. Colgate Oral Health Network for Professional Education and Development. https://www.colga-teoralhealthnetwork.com/article/integrating-the-4ps-into-patient-care/?tab=content. Accessed 19 April 2024
- Confeld M, Griner E, Gres A, Sandroni P, Kuhlman A, Murphy M. Master protocols: the opportunities and challenges of baskets and umbrellas, expanding the translational toolbox. Whitepaper; Worldwide Clinical Trials. November 2023.
- Confeld, M, Murphy MF. When a lethal disease becomes chronic: the emergence of peer rose in oncology. Whitepaper; Worldwide Clinical Trials. March 2024.
 Confeld M, Williamson J, Fishbein G, Murphy M. Leadership in oncology: the culture of improving patient outcomes. Whitepaper; Worldwide Clinical Trials.
- October 2023. • Day IN, Wilson DI: Science, medicine, and the future: genetics and cardiovascular risk. BMJ 2001, 323:1409-1412.
- FDA. Division of Translational and Precision Medicine (DTPM). https://www.fda.gov/about-fda/center-drug-evaluation-and-re-
- search-cder/division-translational-and-precision-medicine-dtpm. Accessed May 5, 2024
- FDA. Focus Area: Individualized Therapeutics and Precision Medicine. https://www.fda.gov/science-research/focus-areas-regulato-
- ry-science-report/focus-area-individualized-therapeutics-and-precision-medicine. Accessed. May 6, 2024. FDA. IND submissions for individualized antisense oligonucleotide's drug products: administrative and procedural recommendation guidance for sponsors-investigators. January 2021. https://www.fda.gov/regulatory-information/search-fda-guid-
- ance-documents/ind-submissions-individualized-antisense-oligonucleotide-drug-products-administrative-and-procedural. Accessed May 5, 2024.
- FDA. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims. Accessed May 6, 2024.
- Frost J, Okun S, Vaughan T, et al. Patient-reported outcomes as a source of evidence in off label prescribing: analysis of data from PatientsLikeMe. J Med Internet Res. 2011;13:e6.
- Gayet-Ageron, A., Rudaz, S. & Perneger, T. Biobank attributes associated with higher patient participation: a randomized study. Eur J Hum Genet 25, 31–36 (2017). https://doi.org/10.1038/ejhg.2016.132
- GlobalData Pharma Intelligence Center. https://www.globaldata.com/industries-we-cover/pharmaceutical/
- Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010 Jul 22;363(4):301-4. doi: 10.1056/NEJMp1006304. Epub 2010 Jun 15. Erratum in: N Engl J Med. 2010 Sep 9;363(11):1092. PMID: 20551152.
- Hapgood R. The potential and limitations of personalized medicine in the doctor-patient relationship. Pharmacogenomics. 2003 Nov 1;4(6):685-7.
- Hood L, Balling R, Auffray C. Revolutionizing medicine in the 21(st) century through systems approaches. Biotechnol J. 2012;7:992-1001.
- Hood L, Flores M. A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. N Biotechnol. 2012 Sep 15;29(6):613-24. doi: 10.1016/j.nbt.2012.03.004. Epub 2012 Mar 18. PMID: 22450380.
- Kahn CR, Vicent D, Doria A: Genetics of non-insulin-dependent (type-II) diabetes mellitus. Annu Rev Med 1996, 47:509-531.
- Los H, Koppelman GH, Postma DS: The importance of genetic influences in asthma. Eur Respir J 1999, 14:1210-1227.
- Meregaglia M, Malandrini F, Angelini S, Ciani O. The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022. Appl Health Econ Health Policy. 2023 Nov;21(6):925-935. doi: 10.1007/s40258-023-00827-3. Epub 2023 Sep 2. PMID: 37659000; PMCID: PMC10627987
- Meyer JM, Ginsburg CS. The path to personalized medicine. Current Opinion in Chemical Biology. 2002 Aug 1;6(4):434-8.
- Murphy M, Badoux J, Zhang T. Fit for purpose biomarker development: a translational medicine perspective, Whitepaper; Worldwide Clinical Trials. July 2023.
 Sprangers MA, Sloan JA, Barsevick A, et al. Scientific imperatives, clinical implications, and theoretical underpinnings for the investigation of the relationship between genetic variables and patient-reported quality-of-life outcomes. Qual Life Res. 2010;19:1395-1403.
- Vieta A, Badia X, Sacristán JA. A systematic review of patient-reported and economic outcomes: value to stakeholders in the decision-making process in patients with type 2 diabetes mellitus. Clin Ther. 2011; 33: 1225-1245.

Where Healthcare Is Customized for Every Individual, Maximizing Treatment Efficacy and Patient Wellness

 \rightarrow